The veteran heart failure cardiologist shares his goals as president, why he thinks his subspecialty is so dynamic these days and what he most wishes other specialists recognized about heart failure care.
Intervening during in-hospital discharge prep is the way to avert heart failure readmissions. That’s the premise behind a novel electronic checklist that has cut our readmission rate to new lows.
Decision-making around LVAD therapy vs. optimal medical care for patients with non-inotrope-dependent heart failure has just gotten better-informed. The ROADMAP trial’s lead investigator explains how.
Two big studies of interest to heart failure specialists were presented at the American College of Cardiology meeting this spring. While STICH was considered positive and INOVATE-HF a disappointment, there’s much more to be gleaned from the nuances of each.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The year just passed was full of insights and innovations likely to be felt for many years to come. Here are 15 such developments in which Cleveland Clinic staff played key roles.
Results from the ROADMAP study provide the first serious look at intervention with a left ventricular assist device for advanced heart failure patients not yet on inotropic drugs. The news is encouraging.
2015 saw the first two approvals of new heart failure drugs in a decade. Here’s how a Cleveland Clinic heart failure expert sees the new agents fitting into the mix of options.
After a long dearth of new heart failure therapies, approval of the neprilysin inhibitor LCZ696 seems imminent – and would follow the unforeseen April approval of the heart-rate-slowing agent ivabradine.
Heart experts at Cleveland Clinic recommend referring patients for a mechanical device (i.e., the LVAD) earlier and outside the context of transplantation. The devices can help improve quantity and quality of life for heart failure patients.
Five new technologies — subcutaneous ICDs, contact force ablation catheters, leadless pacemakers, a vagal nerve stimulator and a left atrial appendage occlusion device — are making EP procedures safer and more effective.